EXJADE (deferasirox)

TherapyNovartis

EXJADE (deferasirox) by Novartis is an oral iron chelator used in transfusion-related iron overload settings.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and EXJADE. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where EXJADE is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Non-Transfusion-Dependent Thalassemia Non-cancer · Blood	Liver iron concentration imaging based on the proton transverse relaxation rate of MRI images		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for EXJADE.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering EXJADE for eligible patients.

Test

FerriScan

Resonance Health Analysis Services Pty Ltd

Method

IMAGING

1 approvalView test profile →

This view is scoped to EXJADE (deferasirox). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.